T
Thomas Machnig
Researcher at Boehringer Ingelheim
Publications - 10
Citations - 8488
Thomas Machnig is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Stroke & Modified Rankin Scale. The author has an hindex of 8, co-authored 9 publications receiving 7693 citations.
Papers
More filters
Journal ArticleDOI
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
Werner Hacke,Markku Kaste,Erich Bluhmki,Miroslav Brozman,Antoni Dávalos,Donata Guidetti,Vincent Larrue,Kennedy R. Lees,Zakaria Medeghri,Thomas Machnig,Dietmar Schneider,Rüdiger von Kummer,Nils Wahlgren,Danilo Toni +13 more
TL;DR: As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; altePlase was more frequently associated with symptomatic intracranial hemorrhage.
Journal ArticleDOI
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Ralph L. Sacco,Hans-Christoph Diener,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +33 more
TL;DR: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel, and there is no evidence that either of the two treatments was superior to the other in the prevention of recurrent strokes.
Journal ArticleDOI
Telmisartan to prevent recurrent stroke and cardiovascular events.
Salim Yusuf,Salim Yusuf,Hans-Christoph Diener,Ralph L. Sacco,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +34 more
TL;DR: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.
Journal ArticleDOI
Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)
Nils Wahlgren,Niaz Ahmed,Niclas Eriksson,Franz Aichner,Erich Bluhmki,Antoni Dávalos,Terttu Erilä,Gary A. Ford,Martin Grond,Werner Hacke,Michael G. Hennerici,Markku Kaste,Martin Köhrmann,Vincent Larrue,Kennedy R. Lees,Thomas Machnig,Risto O. Roine,Danilo Toni,Geert Vanhooren +18 more
TL;DR: The unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCT) when used in routine clinical practice within 3 hours of ischemic stroke onset.
Journal ArticleDOI
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial
Erich Bluhmki,Ángel Chamorro,Antoni Dávalos,Thomas Machnig,C. Sauce,Nils Wahlgren,Joanna M. Wardlaw,Werner Hacke +7 more
TL;DR: The results support the use of alteplase up to 4.5 h after the onset of stroke symptoms across a broad range of subgroups of patients who meet the requirements of the European product label but miss the approved treatment window of 0-3 h.